XML 25 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Debt
9 Months Ended
Dec. 31, 2011
Debt  
Debt

6.              Debt

 

(Dollars in thousands)

 

December 31,
2011

 

March 31,
2011

 

Reducing line of credit

 

$

1,750

 

$

2,500

 

Revolving line of credit

 

 

4,000

 

 

 

1,750

 

6,500

 

Less: current portion

 

1,000

 

5,000

 

Long-term portion

 

$

750

 

$

1,500

 

 

To help finance the acquisition of Apex Laboratories, Inc., SGM Biotech, Inc., and the related building that houses the SGM Biotech facility, the Company entered into a credit facility consisting of: a) 36 month reducing line of credit for $3,000,000 and maturing at April 27, 2013, requiring quarterly principal payments of $250,000 beginning July 27, 2010. In December 2010, the bank deferred the January 27, 2011 payment of $250,000 until maturity at April 27, 2013, which allowed the Company to complete the acquisition of Apex Laboratories, Inc. without further alteration of its existing credit facility; and b) revolving line of credit for $4,000,000 maturing on December 23, 2011, which was retired in December 2011. Both of these lines of credit are subject to a variable rate of interest and a rate floor, both of which were 3.25% at December 31, 2011.  The remaining line of credit requires monthly interest payments, is subject to restrictive covenants and is secured by most of the assets of the Company.  The Company was in compliance with the restrictive covenants as of December 31, 2011.

 

Future maturities of debt are as follows (dollars in thousands):

 

Fiscal year

 

 

 

2012

 

$

250

 

2013

 

1,000

 

2014

 

500

 

 

 

$

1,750